Sagimet Biosciences Inc.

Biotechnology • Healthcare • San Mateo, CA, United States • SGMT (NGM)

650 561 8600 155 Bovet Road, San Mateo, CA 94402, United States

Quarter: Q4 2025 Reported: November 13, 2025 Sentiment: Neutral

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Analysis Summary

The provided document for Sagimet Biosciences Inc. (SGMT) is a Form 8-K filing, specifically Item 2.02 and Item 7.01. It details legal disclaimers concerning the 'filed' status of Exhibit 99.1 under the Securities Exchange Act of 1934 and its incorporation by reference. Item 7.01, a Regulation FD Disclosure, states that on November 13, 2025, the Company updated information in a slide presentation (Exhibit 99.2), which will be utilized in investor meetings. This transcript *does not* contain any financial performance breakdown for Q4 2025, including revenue, net income, EPS, or guidance. It also lacks strategic initiatives, business segment analysis, management commentary, competitive positioning, market trends, risk factors, or analyst Q&A highlights. Therefore, a comprehensive analysis of Sagimet's Q4 2025 performance or outlook cannot be derived from this document.

Key Highlights

• Transcript primarily consists of legal disclaimers for Form 8-K filing.
• Information furnished is not deemed 'filed' for certain legal purposes.
• Company updated an investor slide presentation on November 13, 2025.
• The updated presentation will be used in various meetings with investors.
• No Q4 2025 financial results or operational details are provided in this document.
• No management commentary or forward guidance is included in the transcript.

Financial Metrics

eps

N/A

YoY: Not provided in transcript

revenue

N/A N/A

YoY: Not provided in transcript

guidance

net income

N/A N/A

YoY: Not provided in transcript

Stock Performance (90 Days)

Data through Dec 26, 2025

Layoff Events

Earnings Calls

Positive Signals

• Not determinable from transcript. The document is limited to legal disclosures and a presentation update.
• The company is actively engaging with investors through updated presentations.

Risks & Concerns

— Not determinable from transcript. The document is limited to legal disclosures and a presentation update.
— Absence of Q4 2025 financial performance data prevents assessment of operational risks.
— No specific business or market risks were mentioned in the provided text.